Infusion Options Recalls Bleomycin Infusions Due to Sterility Concerns
Infusion Options, Inc. is recalling Bleomycin 18 Units / 100 mL NS IVPB products in New York due to a lack of assurance of sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score (4) under the rubric, particularly given the risk of infection from non-sterile medical products.
Plain-English summary
Infusion Options, Inc. is recalling Bleomycin 18 Units / 100 mL NS IVPB, a prescription-only intravenous infusion product. The recall was initiated because of a lack of assurance of sterility in the product.
The affected products were distributed in New York only. The recall covers all lots within their expiration dates. No specific lot numbers or dates are provided in the source text.
Consumers and healthcare providers should stop using the affected products and contact Infusion Options, Inc. at 718-283-7233 for further instructions.
The recalled product
- Product
- BLEOMYCIN 18 UNITS / 100 ML NS IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233
- Manufacturer
- Infusion Options, Inc.
- Category
- Drug — Infusion
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots within expiry
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 76 recalled by Infusion Options, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 76 products in this recall →Related recalls
Same manufacturer · Infusion Options, Inc.
See all →- SevereInfusion Options Recalls Calcium Glucunate IV Bags Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Durvalumab Infusions Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Rituximab Infusions Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Fluorouracil Infusions Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Velcade Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
Same hazard · infection
See all →- SevereMedtronic Recalls Grafton DBM Products Due to Donor Microbial Presence
FDA (Devices) · 2026-10-21
- SevereMedtronic Recalls Grafton DBM Allografts Due to Donor Microbial Presence
FDA (Devices) · 2026-10-21
- SevereStryker Bard EP XT Decapolar Steerable Diagnostic EP Catheter Recalled for Sterile Barrier Breach
FDA (Devices) · 2026-10-14
- SevereSafeguard US Operating LLC Recalls Compression Bandages Due to Degradation
FDA (Devices) · 2026-10-14
- HighFDA Recalls Performance Pro Nitrile Gloves Due to Defects
FDA (Devices) · 2026-10-07
Similar recalls
- SevereBaptist Health Recalls Vancomycin IV Bags Due to Sterility Concerns
FDA (Drugs) · 2016-06-08
- SevereAssurance Infusion Recalls Buprenorphine and Fentanyl Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- HighVancomycin Intravenous Solution Recalled Due to Sterility Assurance Issue
FDA (Drugs) · 2023-02-22
- SevereBleomycin Sulfate Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-03-12
- SevereAssurance Infusion Recalls BUP 3.5MG/HYDROM 4MG/ML Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls BUP 1MG//ML/HYDROM 7MG Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22